Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Enveric Biosciences, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 31 | 31 | 0 |
| Shares | 4.78M | 11.0M | +6.17M (+128.9%) |
| Value | $4.45M | $3.61M | −$831.0K (−18.7%) |
New holders (6)
Institutions that held Enveric Biosciences, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hudson Bay Capital Management LP | 4,774,900 | $1.58M | 0.02% |
| Warberg Asset Management LLC | 45,000 | $15.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 20,314 | $7.00K | 0.00% |
| Citigroup Inc | 16,765 | $6.00K | 0.00% |
| JPMorgan Chase & Co | 11,419 | $4.00K | 0.00% |
| Royal Bank of Canada | 1,039 | $0 | 0.00% |
Sold out (6)
Institutions that held Enveric Biosciences, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Pura Vida Investments, LLC | 742,046 | $690.0K |
| Goldman Sachs Group Inc | 58,915 | $55.0K |
| Two Sigma Investments, LP | 42,050 | $39.0K |
| Vident Investment Advisory, LLC | 26,268 | $24.0K |
| Rinkey Investments | 6,500 | $5.00K |
| FNY Investment Advisers, LLC | 40 | $0 |